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Abstract
Background: Recently, mineralocorticoid receptors (MR) were identified in peripheral nociceptive neurons, and
their acute antagonism was responsible for immediate and short-lasting (non-genomic) antinociceptive effects. The
same neurons were shown to produce the endogenous ligand aldosterone by the enzyme aldosterone synthase.
Methods: Here, we investigate whether endogenous aldosterone contributes to inflammation-induced hyperalgesia
via the distinct genomic regulation of specific pain signaling molecules in an animal model of Freund’s complete
adjuvant (FCA)-induced hindpaw inflammation.
Results: Chronic intrathecal application of MR antagonist canrenoate-K (over 4 days) attenuated nociceptive
behavior in rats with FCA hindpaw inflammation suggesting a tonic activation of neuronal MR by endogenous
aldosterone. Consistently, double immunofluorescence confocal microscopy showed abundant co-localization of
MR with several pain signaling molecules such as TRPV1, CGRP, Nav1.8, and trkA whose enhanced expression of
mRNA and proteins during inflammation was downregulated following i.t. canrenoate-K. More importantly,
inhibition of endogenous aldosterone production in peripheral sensory neurons by continuous intrathecal delivery
of a specific aldosterone synthase inhibitor prevented the inflammation-induced enhanced transcriptional
expression of TRPV1, CGRP, Nav1.8, and trkA and subsequently attenuated nociceptive behavior. Evidence for such a
genomic effect of endogenous aldosterone was supported by the demonstration of an enhanced nuclear
translocation of MR in peripheral sensory dorsal root ganglia (DRG) neurons.
Conclusion: Taken together, chronic inhibition of local production of aldosterone by its processing enzyme
aldosterone synthase within peripheral sensory neurons may contribute to long-lasting downregulation of specific
pain signaling molecules and may, thus, persistently reduce inflammation-induced hyperalgesia.
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Introduction
Apart from their role of maintaining the homeostasis of
the body through regulation of numerous physiologic
processes [1, 2], there is increasing evidence for the pres-
ence and functional role of glucocorticoid (GR) and
mineralocorticoid receptors (MR) within the central
nervous system [3–5]. Both genomic and non-genomic
effects of these steroid receptors were described contrib-
uting to an enhanced plasticity of the central nervous
system [3–5].
More recent findings from our laboratory identified
MR mainly on peripheral, CGRP-immunoreactive noci-
ceptive neurons [6], and GR on peripheral and spinal
nociceptive neurons [7], whereas they only scarcely colo-
calized with spinal glia cells or astrocytes. The fact that
GR and MR are localized predominantly on peripheral
and/or spinal nociceptive neurons suggests a pivotal
functional role in the processing of painful stimuli.
Indeed, application of GR agonists and MR antagonists
attenuated nociceptive behavior [7, 8]. This effect oc-
curred immediately and lasted only up to 60min indicat-
ing a non-genomic effect.
Surprisingly, the mRNA and protein of enzyme aldos-
terone synthase, the enzyme that processes the last step
of conversion to aldosterone, were detected in the same
nociceptive neurons [9]. Immunohistochemical double-
staining showed great overlap between aldosterone syn-
thase, aldosterone, and MR in peripheral nociceptive
neurons. Following a localized painful hindpaw inflam-
mation, the expression of aldosterone synthase and the
production of aldosterone were upregulated [9]. Intra-
thecal administration of the MR antagonist canrenoate-
K resulted in an immediate and short-lasting (up to 30
min) reversal of mechanical hypersensitivity most likely
through a non-genomic effect [9].
In contrast to this short-lasting effect, there is no system-
atic investigation on the putative genomic effects of MR on
nociception, particularly on the transcriptional regulation
of certain pain signaling molecules within peripheral noci-
ceptive neurons which contribute to inflammation-induced
hyperalgesia. Covenas et al. [10] provided the first evidence
supporting the notion that MR may stimulate neuronal
peptide synthesis. Moreover, aldosterone selectively in-
creased Na + -K + -ATPase mRNA expression in rat hippo-
campus [11], and chronic intra-cerebroventricular infusion
of aldosterone synthase inhibitor FAD286 or MR blocker
eplerenone reduced epithelial sodium channel c subunit ex-
pression in supraoptic nucleus [12] and hypothalamus [13].
Thus, this study investigated in rats with Freund’s
complete adjuvant-induced hind paw inflammation: (i)
whether chronic i.t. application of the MR antagonist
canrenoate-K attenuates nociceptive behavior, (ii) whether
there is great overlap of MR with specific pain signaling
molecules and whether their expression is affected by MR
receptor blockade, (iii) whether the continuous inhibition
of aldosterone’s production by an i.t. aldosterone synthase
inhibitor will reverse the enhanced expression of pain sig-
naling molecules and subsequently attenuate inflammation-
induced hyperalgesia, and (iv) finally, whether the increased
production of endogenous aldosterone during FCA hind-
paw inflammation leads to enhanced nuclear translocation
of MR supporting the occurrence of genomic effects.
Material and methods
Drugs
Freund’s complete adjuvant (FCA), a water-in-oil emul-
sion of killed mycobacteria (Calbiochem, San Diego,
CA), isoflurane (Abbott, Wiesbaden, Germany), MR se-
lective antagonist canrenoate-K, and aldosterone syn-
thase inhibitor FAD286 were commercially obtained
from Sigma-Aldrich (St. Louis, MO, USA) and were dis-
solved in 0.9% NaCl before application. Drugs were ad-
ministered intrathecally either as single shot or via an
intrathecal (i.t.) catheter as a continuous delivery using
Alzet minipumps (Alzet Corporation, Cupertino, CA).
Animals
Following approval by the local animal care committee
and according to the European Directive (2010/63/EU)
introducing new animal welfare and care guidelines,
experiments were performed in male Wistar rats (180–
250 g) (breeding facility Charité-Universitätsmedizin
Berlin, Germany). Wistar rats received an intraplantar
(i.pl.) injection of 0.15 ml FCA into the right hind paw
under brief isoflurane (1.0–2.5 Vol%) anesthesia. This
treatment consistently produces a local inflammation re-
stricted to the inoculated paw characterized by an in-
crease in paw volume, paw temperature, mechanical
hypersensitivity, and infiltration of various types of im-
mune cells as described previously [14]. All experiments
were performed on the fourth day of FCA hindpaw
inflammation.
Experimental protocols
The first set of experiments examined the potential colo-
calization of MR with the pain signaling molecules
TRPV1, CGRP, Nav1.8, and trkA in sensory L3-5 DRG
neurons of naïve control rats. A second set of experi-
ments assessed the impact of i.t. injection of 40 μg/20 μl
of aldosterone (over four consecutive days) in naïve rats
or 100 μg/20 μl of the MR antagonist canrenoate-K (over
four consecutive days) in rats with FCA hindpaw inflam-
mation on mechanical paw pressure thresholds (PPT).
The i.t. doses chosen are too low to reach effective
plasma concentrations [15, 16] and, thus, will not elicit
any systemic effect [17]. The third set of experiments in-
vestigated the influence of 4 days FCA hindpaw inflam-
mation on significant changes in the aldosterone, MR,
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TRPV1, CGRP, Nav1.8, and trkA expression in sensory
L3-5 DRG neurons ipsilateral to the FCA hindpaw in-
flammation. The doses chosen for each drug were based
on generated dose-response curves in our previous stud-
ies [6–8]. A final set of experiments investigated the ef-
fects of continuous i.t. delivery of the aldosterone
synthase inhibitor FAD286 on mechanical PPT and
neuronal TRPV1, CGRP, Nav 1.8, and trkA expression
after 4 days FCA hindpaw inflammation. For i.t. FAD286
application, Alzet osmotic minipumps (2000 μl, rate 5 μl/
h) were filled with 0.9% NaCl with or without 0.3ug/1 μ1
FAD286 and connected to the i.t. catheter to administer
FAD286 or vehicle continuously at 5 μl/h; an i.t. dose of
1.5 μg/5 μl/h will not lead to effective plasma concentra-
tions and, thus, will not elicit any systemic effect [18].
For i.t. drug administration, animals were anesthetized
with isoflurane in oxygen via nose cone, and a longitu-
dinal skin incision was made in the lumbar region dir-
ectly above the spinous processes of the L3–L5
vertebrae as described previously [19]. Briefly, the i.t.
needle was inserted at a 30° angle between the L4 and
L5 vertebra into the i.t. space and either a single injec-
tion or the placement of an i.t. catheter (PE 10 tubing at-
tached to PE 60 tubing for attachment to an osmotic
pump; Portex Ltd, Hythe, Kent, United Kingdom) was
set up. The sign of dura penetration was observed by in-
voluntary movements of the tail or hind limb and veri-
fied the i.t. space for drug delivery.
Mechanical hyperalgesia testing
The mechanical hyperalgesia following FCA hindpaw in-
flammation was assessed by a mechanical pressure appar-
atus (Ugo-Basile SRL, Monvalle, Italy) with increasing
force (measured in grams) applied to the plantar hind paw
until a withdrawal reflex was precipitated as described
previously [8]. Mechanical paw pressure thresholds (PPT)
which triggered a withdrawal response were determined
in all groups on the fourth day of FCA hindpaw inflamma-
tion. Drug application baseline values were obtained in
both inflamed and contralateral non-inflamed hind paws.
Then, the PPT were reassessed 2 h following the last i.t.
drug administration to determine drug-related behaviors.
PPT measurements were performed 3 times consecutively.
The final PPT were calculated as the mean obtained from
6–7 animals before and after i.t. drug administration. In
all behavioral experiments, drugs were prepared by a dif-
ferent person (M.Sh.), and the examiner (X.L.) was un-
aware of the treatment that each animal received by
chance.
TRPV1, CGRP, Nav1.8, and trkA mRNA detection by
quantitative RT-PCR
Total RNA was extracted from L3-5 dorsal root ganglia
of Wistar rats (n = 5 per experimental group) using
RNeasy Kit (Qiagen, Hilden, Germany) as previously de-
scribed [8, 20]. The following specific primers were gener-
ated and used: for TRPV1, forward primer: AGTGAG
ACCCCTAACCGTCA, reverse primer: CGGAAATAGT
CCCCAACGGT (Ensembl, Accession Nr: NM_031982.1);
for CGRP, forward primer: CCTTTCCTGGTTGTCAGC
ATCTT, reverse primer: CAGTAGGCG AGCTTCTTCT
TCAC (Ensembl, Accession NM_001033956.1); for
Nav.1.8, forward primer: CACGGATGACAACAGGTC
AC, reverse primer; GATCCCGTCAGGAAATGAGA
(Ensembl, Accession Nr: NM_017247.1); for trkA, forward
primer: CCATCCCTGTCT CCTTCTCGC, reverse pri-
mer: CCCAAAAGGTGTTTCGTCCTTC (Ensembl, Ac-
cession Nr: NM_021589.1). Quantitative real-time PCR
(RT-PCR) was performed with a SYBR® Green kit follow-
ing the manufacturer’s instructions (Applied Biosystems,
Carlsbad, CA). Amplification was carried out for 40 cycles,
each consisting of 15 s at 95 °C. A temperature just below
the specific melting temperature (Tm) was employed for
detection of fluorescence specific products (TRPV1: Tm
76 °C, 18S: Tm 83 °C). TRPV1, CGRP, Nav1.8, and trkA
mRNA were quantified using triplicates of samples using
the delta-delta CT method [21, 22].
Aldosterone content measurements in DRG
In deep isoflurane anesthesia rats (n = 7–8 per group)
were sacrificed, L3-5 DRG were quickly removed in
DMEM–Dulbecco’s Modified Eagle Medium (Thermo
Fisher Scientific GmbH Berlin, Germany). DRG were
prepared as described previously [8, 23]. Briefly, 1 mg/ml
collagenase IV was added to the DRG and incubated for
30 min at 37 °C. To stop the collagenase activity, 0.05%
trypsin was added and again incubated for 10 min at
37 °C. Finally, the sample was centrifuged at 500×g for
5 min at room temperature and the pellet resuspended
in 1 ml RPMI 1640 (GibCO, Thermo Fischer, Dreieich,
Germany). After mechanical cell lysis and centrifuga-
tion at 500×g for 5 min, the aldosterone content in
DRG was determined by a commercial kit from R&D
Systems (Minneapolis, MN, USA, Cat. # KGE016). For
this, we followed the protocol according to the manufac-
ture’s manual and our previous study [8]. Briefly, all re-
agents and samples were brought to room temperature
before use. Determinations of aldosterone in the different
samples and standards were done in triplicate as recom-
mended by the manufacture. The optical density of each
well was determined within 30min using a microplate
reader (Infinite M200, Tecan, Männedorf, Switzerland) set
to 450 nm. Then, the average of the triplicate readings for
each standard, control and sample were determined and
subtracted by the average NSB optical density (O.D.). A
standard curve was created using the computer software
Magellan Vers. 7.2 (Tecan, Männedorf, Switzerland)
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capable of generating a four-parameter logistic (4-PL)
curve-fit. The results were calculated by wet weight.
Immunohistochemistry
After transcardial perfusion of rats L3-L5 DRG were re-
moved and further processed as described previously [6, 8],
slide mounted tissue sections (8 μm) were obtained by
using a kryostat (Microm,Thermo Fischer, Dreieich,
Germany). Tissue sections were then incubated overnight
with the following primary antibodies (see also supplemen-
tal table 1): mouse antibody against MR (private gift from
Prof. Elise Gomez-Sanchez, Jackson, USA) was examined
alone or in combination with a polyclonal rabbit anti-
Nav1.8 (Sigma-Aldrich, USA), guinea pig anti-CGRP, goat
anti-trkA (R&D Systems, USA) or goat anti-TRPV1 (Santa
Cruz Biotechnology, California): in addition, polyclonal
rabbit anti-aldosterone (Novus Biologicals, CO, USA) alone
or in combination with the polyclonal guinea pig anti-
CGRP or monoclonal mouse anti-MR. The species,
sources, dilutions, and immunogens of the primary anti-
bodies used in this study are summarized in the supple-
mental table 1. Finally, the tissues were washed in PBS,
mounted on vectashield (Vector Laboratories), and imaged
with a confocal laser scanning microscope, LSM510 as
described previously [8]. To demonstrate specificity of
staining, the following controls were included as described
in our previous studies [7, 8, 20]: omission of either the
primary antisera or the secondary antibodies.
The quantification of DRG staining has been described
previously [7, 8, 20]. Quantification of immunofluores-
cence of MR, TRPV1, CGRP, Nav1.8, and trkA in DRG
tissue sections was performed by using the Zeiss Zen 2009
software Carl Zeiss Micro-Imaging GmbH (Göttingen,
Germany). For counting of the total number of neurons,
only those immunostained neurons containing a distinct
nucleus were counted. In a similar way, the number of
aldosterone-ir DRG cells/320μm2, MR-ir DRG cells/
320μm2, TRPV1-ir DRG cells/320μm2, CGRP-ir DRG
cells/320μm2, Nav1.8-ir DRG cells/320μm2, and trkA-ir
DRG cells/320μm2 cells was counted in each DRG section
and represented as percentages. Data were obtained from
4–6 rats per group using × 40 objective lens.
Preparation and immunoblotting of cytosol and nuclear
extract
The isolated DRG neurons from control or FCA treated
animals were washed three times in ice cold HANKs
solution (10,000 rpm/3 min) to remove any remaining
medium or buffer from the previous step of cell isolation.
For extraction of cytoplasma, the supernatent was carefully
removed and the cell pellet resuspended in cytoplasmic ex-
traction buffer (10mM HEPES, 10mM KCl, 0.1mM
EDTA, 0.1mM EGTA) containing 0.1mM DTT, 0.1mM
PMSF, 2 μg/ml leupetin, 2 μg/ml aprotinin, 0.5mg/ml
benzamidin, and incubated on ice for 30min. Then, 10%
NP-40 was added, each sample vortexed for 30 s, centri-
fuged (10 000 rpm/3min), and the supernatant (cytosol ex-
tract) transferred to a new tube and stored at − 80 °C. For
further preparation of the nuclear extract, the remaining
pellet (containing the nuclei) was re-suspended in nuclear
extraction buffer (20mM HEPES, 400mM NaCl, 1mM
EDTA, 1mM EGTA) containing 1mM DTT, 0.5mM
PMSF, 2 μg/ml leupetin, 2 μg/ml aprotinin, 0.5mg/ml ben-
zamidin, and incubated for 30min on ice. Finally, samples
were centrifuged (10,000 rpm/3min), and supernatant con-
taining nuclear extract was transferred to a new tube and
stored at − 80 °C. The total protein content in samples was
measured using the bicinchinonic acid system (Uptima,
France), the samples were reduced with 2-mercaptoethanol,
and the protein contents were adjusted. The samples were
separated by SDS-PAGE electrophoresis (7% gels), trans-
ferred to a nitrocellulose membrane, washed for 2 h with
skimmed milk buffer for unspecific blocking, and incubated
with primary antibodies for mineralocorticoid receptor
(rMR), Poly (ADP-ribose) polymerase (PARP), or β-actin
overnight at 4 °C. Finally, the membranes were washed
three times with skimmed milk buffer, incubated with sec-
ondary antibodies for 2 h, and antibody-antigen complexes
visualized by nitro-blue tetrazolium and 5-bromo-4-chloro-
3-indoylphosphate (p-toluidine salt; Pierce, Rockford,
USA). Experiments were done in 6 animals per group in
duplicate.
The Western blot band specific for rMR (107 kDa) or
PARP (110 kDa) was quantified by the Java Image pro-
cessing and analysis software (Image J, open-source
image software downloaded from the web1 [6, 7]. The
area and density of pixels within the threshold values
representing immunoreactivity were measured, and the
integrated density (the product of the area and mean of
grey values) was calculated. Integrated immunodensities
of controls and treated groups were compared and sta-
tistically analysed [19].
Statistical analysis
All tests were performed using the Sigma Stat 2.03 soft-
ware (SPSS Inc., Germany). Quantitative RT-PCR,
Western blot, and immunofluorescence data were ana-
lyzed as two group comparisons (FCA treated rats ver-
sus controls) by a two-tailed independent Student t test
in case of normally distributed data. Three group com-
parisons were done for quantitative RT-PCR and im-
munohistochemistry experiments by one-way ANOVA
followed by a post-hoc Dunnett’s test. Paw pressure
thresholds (PPT) were determined before and after
drug injections within the same group of animals,
expressed as means ± SD, and statistically analyzed by a
1http://rsb.info.nih.gov/ij/. Last accessed November 28, 2018
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repeated measurement-ANOVA, followed by post-hoc
Dunnett’s test. For all statistical tests, significance was
assumed at P < 0.05.
Results
Chronic antagonism of endogenous aldosterone or
administration of exogenous aldosterone reveals
aldosterone’s contribution to an enhanced mechanical
hypersensitivity
Four days of FCA-induced inflammation of the right
hindpaw resulted in diminished mechanical PPT
thresholds in inflamed compared to non-inflamed
hindpaws (dashed line, Fig. 1) (P < 0.05, repeated
measurement-ANOVA, followed by post-hoc Dun-
nett’s test, Fig. 1a). This enhanced mechanical hyper-
sensitivity in inflamed hindpaws was significantly
attenuated following daily i.t. administrations of the
MR selective antagonist canrenoate-K (P < 0.05, re-
peated measurement-ANOVA, followed by post-hoc
Dunnett’s test; Fig. 1a). Canrenoate-K had no effect
on the contralateral non-inflamed hindpaw (data not
shown), similar to previous reports in naive rats [8].
Conversely in naïve control rats, repeated i.t. admin-
istration of the MR selective agonist aldosterone over
4 days resulted in a significant decrease of mechanical
PPT thresholds and, thus, enhanced sensitivity to mechan-
ical stimuli (P < 0.05, repeated measurement-ANOVA,
followed by post-hoc Dunnett’s test; Fig. 1b), while vehicle
administration did not significantly alter mechanical PPT
(P < 0.05, repeated measurement-ANOVA, followed by
post-hoc Dunnett’s test; Fig. 1b).
Chronic intrathecal MR antagonism inhibits the enhanced
transcription of pain signaling molecules colocalizing
with MR during inflammatory pain
Our double immunofluorescence confocal microscopy
showed abundant colocalization of MR with several pain
signaling molecules such as TRPV1, CGRP, Nav1.8, and
trkA (TRPV1 68%; CGRP 79%; Nav1.8 74 %; trkA 56%)
(Fig. 2). To investigate potential genomic effects of MR
on the expression of these pain signaling molecules, we
repeatedly treated rats with FCA hindpaw inflammation
over 4 days with i.t. administration of the MR antagonist
canrenoate-K (Fig. 3a–d). Indeed, the significantly en-
hanced mRNA expression of pain signaling molecules
TRPV1, CGRP, Nav1.8, and trkA in sensory DRG ipsilat-
eral to the FCA hindpaw inflammation was significantly
attenuated by chronic i.t. canrenoate-K delivery (P < 0.05,
one-way ANOVA, followed by Dunnett’s test; Fig. 3a–d).
Consistent with these findings, the significantly in-
creased numbers of TRPV1-, CGRP-, Nav1.8-, and
trkA-immunoreactive DRG neurons ipsilateral to the
FCA hindpaw inflammation were significantly reduced
by chronic i.t. canrenoate-K administration (P < 0.05,
one-way ANOVA, followed by Dunnett’s test; Fig. 4a–p),
although the total number of DRG cells was not signifi-
cantly altered (Ctrl 45 ± 8.5; FCA 45 ± 8.8; FCA + Can
42 ± 12, P = 0.43 one-way ANOVA).
Enhanced MR translocation to the nucleus of DRG
neurons during inflammatory pain
Following several steps of DRG cell extract separation into
a nuclear and cytosolic fraction subsequent western blot
analysis identified a MR specific protein band at 107 kDa in
Fig. 1 Role of mineralocorticoid receptor (MR) specific antagonist canrenoate-K (Can) in the modulation of Freund’s complete adjuvant (FCA)
inflammation-induced nociceptive behavior. a, b Four days FCA inflammation of the right hindpaw resulted in significantly reduced mechanical
PPT thresholds compared to baseline values (dotted line) (P < 0.05, repeated measurement-ANOVA, followed by post-hoc Dunnett’s test; n = 6).
Chronic i.t. canrenoate-K reversed this mechanical hypersensitivity (P < 0.05, repeated measurement-ANOVA, followed by post-hoc Dunnett’s test;
n = 6). Data are expressed as means ± SD. b In contrast, i.t. administration of repetitive doses of the exogenous aldosterone resulted in significant
PPT reductions compared to baseline (0 min) indicating a reduced mechanical nociceptive thresholds (hyperalgesia) ( P < 0.05, repeated
measurement-ANOVA, followed by post-hoc Dunnett’s test; n = 6). Data are expressed as means ± SD
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both fractions (Fig. 5a, b). The detection of PARP (110
kDa), which is a nuclear specific enzyme for DNA repair,
validated the nuclear fraction, whereas the detection of ß-
actin verified the cytosolic fraction (Fig. 5a, b). In the
nuclear but not cytosolic fraction, DRG innervating the in-
flamed hindpaws of rats showed a significant increase in
the density of the MR protein band compared to those
DRG innervating non-inflamed hindpaws (P < 0.05, Stu-
dent’s t test; Fig. 5a, b). This was confirmed by immunohis-
tochemistry of the respective DRG showing an increasing
overlap of MR-immunoreactivity with the nuclear DAPI
staining indicating enhanced nuclear translocation follow-
ing 4 days of FCA-induced hindpaw inflammmation.
Chronic intrathecal aldosterone synthase inhibition
prevents the enhanced expression of pain signaling
molecules and the elevated mechanical sensitivity during
inflammatory pain
Since aldosterone synthesized in peripheral sensory DRG
neurons seemed to contribute to inflammatory pain in
rats with FCA hindpaw inflammation, we examined
whether continuous i.t. infusion of aldosterone synthase
inhibitor FAD286 diminished aldosterone synthesis in
DRG of inflamed rats to that of controls. Indeed, i.t. in-
fusion of FAD286 but not vehicle in FCA treated rats
significantly reduced the number of aldosterone-IR DRG
neurons determined by immunofluorescence confocal
analysis (P < 0.05, Student’s t test; Fig. 6a–c), although
the total number of DRG cells was not significantly al-
tered (Ctrl 45 ± 8.5; FCA 45 ± 8.8; FCA + FAD 40 ± 6.7,
P = 0.433 one-way ANOVA). Moreover, aldosterone
specific ELISA experiments revealed that the increase in
aldosterone DRG content of FCA animals was also sig-
nificantly diminished following i.t. aldosterone synthase
inhibitor FAD286 (P < 0.05, Student’s t test; Fig. 6d). To
verify whether the reduced aldosterone content in DRG
would affect the enhanced expression of the pain signal-
ing molecules TRPV1, CGRP, Nav1.8, and trkA follow-
ing FCA hindpaw inflammation, we examined DRG
neuron mRNA as well as the number of DRG neurons
Fig. 2 Detection of mineralocorticoid receptor (MR) with pain signaling molecules TRPV1, CGRP, Nav1.8, and trkA in dorsal root ganglia (DRG) of
control rats. a–d Double immunofluorescence confocal microscopy of MR (red fluorescence) with TRPV1, CGRP, Nav1.8, and trkA (green
fluorescence) in DRG sections (Bar = 40 μm). a–d The majority of MR-IR DRG sensory neuron express TRPV1, CGRP, Nav1.8, and trkA in control
animals (Bar = 40 μm). Data are expressed as means ± SD; n = 7–12
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containing these molecules following chronic i.t. admin-
istration of aldosterone synthase inhibitor FAD286. This
treatment significantly prevented the inflammation-
induced increase in mRNA (P < 0.05, Student’s t test;
Fig. 6e–h) and in the number of TRPV1-, CGRP-,
Nav1.8-, and trkA-IR nociceptive DRG neurons (P <
0.05, Student’s t test; Fig. 7a–l). Concomitant with this
prevention, the FCA-induced enhanced mechanical
hypersensitivity was significantly reduced following i.t.
FAD286 (P < 0.05, Student’s t test; Fig. 7m).
Discussion
For the first time, we have systematically investigated
the potential long-lasting genomic effects of endogenous
MR agonist aldosterone on the transcriptional regulation
of several pain signaling molecules in peripheral sensory
DRG neurons during inflammatory pain. Previous studies
have demonstrated MR and its endogenous ligand aldoster-
one in these neurons [8, 9]. Here, chronic i.t. antagonism of
endogenous aldosterone during hindpaw inflammation or,
conversely, chronic application of exogenous aldosterone in
animals without hindpaw inflammation attenuated or
evoked mechanical hypersensitivity, respectively. Since the
i.t. doses chosen are too low to elicit systemic effects, the
findings suggest a persistent endogenous tonic activation of
neuronal MR during local inflammation. Interestingly,
double immunofluorescence confocal microscopy showed
abundant colocalization of MR with several pain signaling
molecules such as TRPV1, CGRP, Nav1.8, and trkA.
Moreover, continuous (over 4 days) inhibition of en-
dogenous aldosterone production in peripheral sensory
neurons by i.t. application of the specific aldosterone
synthase inhibitor FAD286 prevented the enhanced
transcriptional expression of pain signaling molecules
TRPV1, CGRP, Nav1.8, and trkA and subsequently
attenuated the nociceptive behavior during hindpaw in-
flammation. This genomic effect of endogenous aldos-
terone during inflammatory pain was supported by the
demonstration of an enhanced translocation of MR
from the cytosol to the nucleus in peripheral sensory
DRG neurons.
Previously, we have demonstrated that the final con-
version of 18-hydroxycorticosterone into aldosterone by
aldosterone synthase also occurs in peripheral sensory
DRG neurons [9] confirming preceding reports on the
expression of aldosterone synthase outside the adrenal
gland, e.g., in brain, heart, aortic endothelial cells, and in
vascular smooth muscle [24–26]. Moreover, we have
shown that a single systemic or intrathecal administra-
tion of the MR antagonist canrenoate-K resulted in an
immediate and short-lasting (up to 30 min) reversal of
mechanical hypersensitivity most likely through a non-
genomic effect [9]. In contrast to this short-lasting effect,
we investigated in this study whether chronic antagon-
ism of aldosterone’s action or continuous inhibition of
aldosterone synthesis (over 4 days) resulted in alterations
of the genomic expression of specific pain signaling
molecules such as TRPV1, CGRP, Nav1.8, and trkA and
Fig. 3 MR selective antagonist canrenoate-K reversed the enhanced expression of pain signaling molecules TRPV1 (a), CGRP (b), Nav1.8 (c), and
trkA (d) mRNA in nociceptive DRG neurons with inflammatory pain. a–d Chronic i.t. canrenoate-K administration to rats with Freund’s complete
adjuvant (FCA)-induced inflammation reversed the enhanced expression of pain signaling molecules TRPV1 (a), CGRP (b), Nav1.8 (c), and trkA (d)
mRNA. (P < 0.05, one-way ANOVA, followed by post-hoc Dunnett’s test, n = 10). Data are expressed as means ± SD
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whether this resulted in changes of nociceptive behavior
following FCA-induced hindpaw inflammation.
First, we demonstrated that chronic i.t. administration
of the MR selective antagonist canrenoate-K attenuated
mechanical hypersensitivity in inflamed hindpaws sug-
gesting a tonic activation of neuronal MR by endogen-
ous aldosterone. Conversely, chronic i.t. administration
of exogenous aldosterone in naïve rats resulted in mech-
anical hypersensitivity. Previous studies have demon-
strated that the MR-immunoreactivity within the dorsal
horn of the spinal cord mainly derives from peripherally
incoming CGRP-ir nociceptive neurons in Rexed
laminae I and II, and only few scattered neuronal cells
were identified in Rexed laminae III and IV [6]. Al-
though the corticosterone inactivating enzyme 11ßHSD2
colocalized with sensory neuron MR allows MR activa-
tion predominantly by aldosterone [8], the co-activation
by corticosterone cannot be fully excluded. Our findings
are in agreement with older studies which have shown a
long-lasting analgesic effect of MR antagonists [27, 28].
Then, we found that several potential pain signaling
molecules such as TRPV1, CGRP, Nav1.8, and trkA
showed a 60–75% overlap with MR-immunoreactive
DRG neurons, which is consistent with previous studies
Fig. 4 MR selective antagonist canrenoate-K reversed the enhanced expression of pain signaling molecules TRPV1 (a), CGRP (b), Nav1.8 (c), and
trkA (d) immunoreactivity in nociceptive DRG neurons with inflammatory pain. a–d Chronic i.t. canrenoate-K administration to rats with Freund’s
complete adjuvant (FCA)-induced inflammation reversed the increased number of pain signaling molecules TRPV1 (a), CGRP (b), Nav1.8 (c), and
trkA (d) IR DRG neurons. (P < 0.05, one-way ANOVA, followed by post-hoc Dunnett’s test, n = 9–17) (Bar = 40 μm). Data are expressed as means
± SD
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Fig. 5 Western blot of whole protein extracts of dorsal root ganglia (DRG) nuclei and cytosol fractions of rats with hindpaw inflammation versus
control (Ctrl) with anti-mineralocorticoid receptor (MR), Poly(ADP-ribose)polymerase (PARP), or ß-actin antibody. a, b Western blots of the nuclear
and cytosol fractions were verified by the detection of the nuclear component Poly(ADP-ribose)polymerase (PARP) (110 kDa) and the cytosol
component ß-actin (43 kDa), respectively. In both the nuclear and cytosol fractions MR (107 kDa), specific protein was detected under inflamed
and control conditions. However, nuclear fractions from DRG innervating inflamed hindpaws showed a significant 8-fold increase in the density
of the MR protein compared to control DRG (P < 0.05, two-tailed independent Student’s t test; n = 6). c, d Confocal microscopy showing
increasing overlap of MR-immunorecativity (red fluorescence) with nuclear DAPI (blue fluorescence) staining of DRG of FCA-treated rats
versus controls
Fig. 6 Aldosterone synthase inhibitor FAD286 reversed the elevated aldosterone content as well as enhanced expression of pain signaling
molecules TRPV1, CGRP, Nav1.8, and trkA mRNA in nociceptive dorsal root ganglia (DRG) neurons with inflammatory pain. a, b Determination of
aldosterone-immunoreactive (IR) DRG neurons of FCA rats treated with i.t. aldosterone synthase inhibitor FAD286. Note, the number of
aldosterone-IR DRG neurons of FCA rats was increased by approximately 2.2-fold compared to controls which was reversed following continuous
i.t. aldosterone synthase inhibitor FAD286 treatment over 5 days (b) (P > 0.05, two-tailed independent Student’s t test; n = 7–11). c Determination
of aldosterone content in DRG of FCA rats treated with i.t. aldosterone synthase inhibitor FAD286 by a fluorometric enzyme-linked immunoassay.
Note, aldosterone content in DRG of FCA rats was increased by approximately 2.6-fold compared to control which was reversed following i.t.
adosterone synthase inhibitor FAD286 treatment (P < 0.05, two-tailed independent Student’s t test; n = 7,8). e–h Long-lasting i.t. aldosterone
synthase inhibitor FAD286 to rats with Freund’s complete adjuvant (FCA)-induced inflammation reversed the enhanced expression of pain
signaling molecules TRPV1 (e), CGRP (f), Nav1.8 (g), and trkA (h) mRNA. (P < 0.05, two-tailed independent Student’s t test; n = 5). Data are
expressed as means ± SD
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on the identification of certain subpopulations of MR
expressing peripheral sensory neurons [6, 7]. In general,
literature on a potential colocalization of neuronal MR
with pain signaling molecules is scarce. Derbenev et al.
for example reported about a putative colocalization of
GR with TRPV1, since whole-cell patch-clamp record-
ings in the dorsal nucleus of the vagal nerve showed
GR-mediated activation of TRPV1 receptors on afferent
terminals [29]. In line with older reports [10, 30, 31]
about a coexistence of GR with the spinal neuropeptides
substance P and CGRP, our previous studies have dem-
onstrated that MR and GR colocalize with CGRP in
DRG neurons [6, 7].
Furthermore, our data show that the expression of
these pain signaling molecules TRPV1, CGRP, Nav1.8,
and trkA is upregulated in DRG neurons ipsilateral to
the local hindpaw inflammation consistent with numer-
ous older studies [32–35]. Interestingly, chronic i.t. ad-
ministration of the MR antagonist canrenoate-K in rats
with FCA-induced hindpaw inflammation caused a
downregulation of the mRNA and immunoreactivity of
these pain signaling molecules in DG neurons suggesting
that an intrinsic tonic activation of sensory neuron MR
by endogenous aldosterone may contribute to this up-
regulation. Importantly, this downregulation in various
pain signaling molecules was not caused by a decrease in
the total number of DRG cells according to our results.
What is the most likely mechanism? It is widely
accepted that aldosterone functions by binding to the
intracellular MR, a ligand-activated transcription factor
and member of the nuclear hormone receptor family,
resulting in late genomic effects [36, 37] [10]. provided
the first evidence for the notion that the MR agonist
aldosterone stimulates the upregulation of substance P
and somatostatin after adrenalectomy by a genomic
mechanism. Moreover, aldosterone, through its inter-
action with the MR, increased transient receptor poten-
tial canonical 1 and 6 expression in the adrenal medulla
Fig. 7 Aldosterone synthase inhibitor FAD286 reversed the enhanced expression of pain signaling molecules TRPV1, CGRP, Nav1.8, and trkA
immunoreactivity in nociceptive dorsal root ganglia (DRG) neurons as well as mechanical hyperalgesia during inflammatory pain. a–l Continuous
i.t. aldosterone synthase inhibitor FAD286 infusion to rats with Freund’s complete adjuvant (FCA)-induced inflammation reversed the increased
number of pain signaling molecules TRPV1- (a–c), CGRP- (d–f), Nav1.8- (g–i), or trkA- (j–l) IR DRG neurons. (P < 0.05, two-tailed independent
Student’s t test; n = 9–17) (Bar = 40 μm). Data are expressed as means ± SD. m Continuous i.t. aldosterone synthase inhibitor FAD286 infusion
resulted in significant PPT elevations compared to baseline (0 min) indicating a reversal of FCA inflammation-induced mechanical hyperalgesia (P
< 0.05, repeated measurement-ANOVA, followed by post-hoc Dunnett’s test; n = 6–10)
Shaqura et al. Journal of Neuroinflammation          (2020) 17:183 Page 10 of 13
of metabolic syndrome pigs [38–40]. In a similar way, al-
dosterone selectively increased Na+-K+-ATPase mRNA
expression in rat hippocampus [11]. Similarly, chronic
intra-cerebroventricular infusion of aldostrone synthase
inhibitor FAD286 or MR blocker eplerenone reduced
epithelial sodium channel C subunit expression in the
supraoptic nucleus [12] and hypothalamus [13]. Taken
together, this emerging evidence suggests that neuronal
aldosterone may play a potential role in the transcrip-
tional regulation of pain signaling molecules in periph-
eral sensory neurons.
A genomic effect of neuronal aldosterone is further
supported by our demonstration of an enhanced trans-
location of MR from the cytosol to the nucleus of per-
ipheral sensory DRG neurons. Following fractionation of
homogenized DRG into a nuclear and a cytosolic com-
partment, MR were identified in both DRG of control
rats and DRG of rats with an inflamed hindpaw. How-
ever, the intensity of the protein band was 8-fold higher
in the nuclear than the cytosolic compartment under in-
flammatory pain conditions indicating an enhancement
of nuclear translocation and, thus, supporting a genomic
mechanism. This notion was confirmed by immunohis-
tochemistry of the respective DRG showing an increased
overlap of MR-immunorecativity with the nuclear
marker DAPI and was supported by similar demonstra-
tions of MR nuclear translocation within sensory affer-
ent neurons of the cochlea [41] and striatum [42].
The next question arises: what are the functional con-
sequences of blocking the 18-hydroxycorticosterone
conversion into aldosterone via long-lasting inhibition of
aldosterone synthase in nociceptive neurons? Since al-
dosterone content of peripheral sensory DRG was sig-
nificantly elevated following inflammation, we examined
whether i.t. infusion of aldosterone synthase inhibitor
FAD286 reduced the aldosterone content in DRG of in-
flamed rats to control levels. Indeed, chronic i.t. infusion
of FAD286 over 4 days significantly reduced aldosterone
content as well as the number of aldosterone-IR DRG
neurons in FCA rats. Consequently, this FAD286-
mediated aldosterone reduction during FCA hindpaw in-
flammation not only reversed the enhanced expression
of the pain signaling molecules TRPV1, CGRP, Nav1.8,
and trkA, but also attenuated nociceptive behavior. Our
findings of a transcriptional regulation of pain signaling
molecules and subsequent nociceptive behavior are con-
sistent with older studies [27, 28] which showed a long-
lasting analgesic effect of MR antagonists.
Conclusion
In summary, our present study demonstrates that long-
lasting blockade of endogenous aldosterone from activat-
ing MR on sensory DRG neurons during local inflamma-
tion not only prevents the enhanced transcriptional
expression of pain signaling molecules such as TRPV1,
CGRP, Nav1.8, and trkA within peripheral sensory neu-
rons but also subsequently attenuates mechanical hyper-
sensitivity. This genomic effect of endogenous aldosterone
during inflammatory pain was supported by the demon-
stration of an enhanced nuclear translocation of MR in
peripheral sensory DRG neurons. Together, these findings
suggest that local production of aldosterone within per-
ipheral sensory DRG contributes to ongoing mechanical
hypersensitivity via continuous activation of neuronal MR,
most likely through genomically regulated enhanced
expression of pain signaling molecules.
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